{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T14:23:23Z","timestamp":1762957403416,"version":"3.41.2"},"reference-count":22,"publisher":"Vilnius University Press","issue":"1","license":[{"start":{"date-parts":[[2024,9,17]],"date-time":"2024-09-17T00:00:00Z","timestamp":1726531200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["AML"],"abstract":"<jats:p>Background: Inflammatory bowel disease (IBD)` may affect organs outside the intestines, it is called extraintestinal manifestations of IBD. Data on the prevalence of mu-cocutaneous manifestations in IBD patients are very limited, therefore, the aim of this study was to assess the prevalence of skin and mucosal lesions and to determine the relationship with demographic factors, clinical features, and systemic treatment.Materials and methods:\u00a0Prospective study included 162 out-patients with IBD who were managed in the tertiary care center. Ulcerative colitis (UC) was diagnosed in 117 patients, Crohn\u2018s disease (CD) in 45. Patients completed the questionnaire containing demographic and IBD data, questions about mucocutaneous lesions (in past or present state).Results:\u00a0Overall mucocutaneous lesions were reported by 48.1% of IBD patients. Skin lesions were reported by 40.7% of patients, oral mucosal lesions were reported by 16.7%, without significant differences between sexes or IBD types. In 47 (29%) of patients, skin lesions appeared together with IBD or during the course of the disease. The most common skin lesions were psoriasis (8.0%), erythema nodosum (5.6%), pyoderma gangrenosum and acne (3.7% each). UC patients mostly reported about psoriasis (9.4%), while CD patients about erythema nodosum (11.1%). There were more frequent skin lesions in patients with more extensive UC type (p = 0.01), while no difference was noticed between different types of CD. The average duration of IBD in patients with skin lesions was similar to those without lesions (9.3\u00b16.7 vs. 9.4\u00b16.7 years).Conclusions:\u00a0Mucocutaneous lesions were reported by 48.1% of inflammatory bowel disease patients. The frequency of mucocutaneous lesions does not differ significantly between UC and CD, and a longer duration of illness is not a predictive factor for the appearance of lesions. More extensive UC is related to higher frequency of skin lesions.\nErratum noteThe title, author's name, and abstract have been updated to reflect the correct information following a typographical error during typesetting. We apologize for any inconvenience caused by these errors. Corrections were made on 2024-09-01.<\/jats:p>","DOI":"10.15388\/amed.2024.31.1.23","type":"journal-article","created":{"date-parts":[[2024,5,28]],"date-time":"2024-05-28T23:30:23Z","timestamp":1716939023000},"page":"103-112","source":"Crossref","is-referenced-by-count":1,"title":["Mucocutaneous Manifestations Reported by Inflammatory Bowel Disease Patients in University Hospital"],"prefix":"10.15388","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-5541-5089","authenticated-orcid":false,"given":"Ieva Renata","family":"Jonaityt\u0117","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-2513-7269","authenticated-orcid":false,"given":"Vita","family":"Karpavi\u010di\u016bt\u0117","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5945-8284","authenticated-orcid":false,"given":"Gediminas","family":"Kiudelis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8760-7416","authenticated-orcid":false,"given":"Juozas","family":"Kup\u010dinskas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9086-3675","authenticated-orcid":false,"given":"Laimas","family":"Jonaitis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"6097","published-online":{"date-parts":[[2024,9,17]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"GBD 2017 Inflammatory Bowel Disease Collaborators. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2020;5(1):17-30. doi:10.1016\/S2468-1253(19)30333-4","DOI":"10.1016\/S2468-1253(19)30333-4"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Kiudelis G, Jonaitis L, Adamonis K, \u017dvirblien\u0117 A, Tamelis A, Kreg\u017edyt\u0117 R, Ku\u010dinskien\u0117 R, \u0160ventoraityt\u0117 J, Kup\u010dinskas L. Incidence of inflammatory bowel disease in Kaunas region, Lithuania. Medicina (Kaunas). 2012;48(8):431-435. doi:10.3390\/medicina48080064","DOI":"10.3390\/medicina48080064"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2017;390(10114):2769-2778. doi:10.1016\/S0140-6736(17)32448-0","DOI":"10.1016\/S0140-6736(17)32448-0"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Karpavi\u010di\u016bt\u0117 V, Kiudelis G, Kup\u010dinskas J, Kup\u010dinskas L. Trends in the Prevalence of Inflammatory Bowel Disease in Lithuania during 2001-2020. J Crohn's Colitis. 2023;17:965-966. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjac190.0966","DOI":"10.1093\/ecco-jcc\/jjac190.0966"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Rogler G, Singh A, Kavanaugh A, Rubin DT. Extraintestinal Manifestations of Inflammatory Bowel Disease: Current Concepts, Treatment, and Implications for Disease Management. Gastroenterology. 2021;161(4):1118-1132. doi:10.1053\/j.gastro.2021.07.042","DOI":"10.1053\/j.gastro.2021.07.042"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Vavricka SR, Rogler G, Gantenbein C, et al. Chronological Order of Appearance of Extraintestinal Manifestations Relative to the Time of IBD Diagnosis in the Swiss Inflammatory Bowel Disease Cohort. Inflamm Bowel Dis. 2015;21(8):1794-1800. doi:10.1097\/MIB.0000000000000429","DOI":"10.1097\/MIB.0000000000000429"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Karmiris K, Avgerinos A, Tavernaraki A, et al. Prevalence and Characteristics of Extra-intestinal Manifestations in a Large Cohort of Greek Patients with Inflammatory Bowel Disease. J Crohns Colitis. 2016;10(4):429-436. doi:10.1093\/ecco-jcc\/jjv232","DOI":"10.1093\/ecco-jcc\/jjv232"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Topalo\u011flu Demir F, Kocat\u00fcrk E, Yorulmaz E, Adal\u0131 G, Kavala M. Mucocutaneous manifestations of inflammatory bowel disease in Turkey. J Cutan Med Surg. 2014;18(6):397-404. doi:10.2310\/7750.2014.13209","DOI":"10.2310\/7750.2014.13209"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Zippi M, Corrado C, Pica R, et al. Extraintestinal manifestations in a large series of Italian inflammatory bowel disease patients. World J Gastroenterol. 2014;20(46):17463-17467. doi:10.3748\/wjg.v20.i46.17463","DOI":"10.3748\/wjg.v20.i46.17463"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Greuter T, Navarini A, Vavricka SR. Skin Manifestations of Inflammatory Bowel Disease. Clin Rev Allergy Immunol. 2017;53(3):413-427. doi:10.1007\/s12016-017-8617-4","DOI":"10.1007\/s12016-017-8617-4"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Antonelli E, Bassotti G, Tramontana M, et al. Dermatological Manifestations in Inflammatory Bowel Diseases. J Clin Med. 2021;10(2):364. doi:10.3390\/jcm10020364","DOI":"10.3390\/jcm10020364"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Garcovich S, De Simone C, Genovese G, Berti E, Cugno M, Marzano AV. Paradoxical Skin Reactions to Biologics in Patients With Rheumatologic Disorders. Front Pharmacol. 2019;10:282. doi:10.3389\/fphar.2019.00282","DOI":"10.3389\/fphar.2019.00282"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Nigam GB, Bhandare AP, Antoniou GA, Limdi JK. Systematic review and meta-analysis of dermatological reactions in patients with inflammatory bowel disease treated with anti-tumour necrosis factor therapy. Eur J Gastroenterol Hepatol. 2021;33(3):346-357. doi:10.1097\/MEG.0000000000001917","DOI":"10.1097\/MEG.0000000000001917"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Russell MD, Stovin C, Alveyn E, et al. JAK inhibitors and the risk of malignancy: a meta-analysis across disease indications. Ann Rheum Dis. 2023;82(8):1059-1067. doi:10.1136\/ard-2023-224049","DOI":"10.1136\/ard-2023-224049"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Curtis JR, Yamaoka K, Chen YH, et al. Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial. Ann Rheum Dis. 2023;82(3):331-343. doi:10.1136\/ard-2022-222543","DOI":"10.1136\/ard-2022-222543"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Weizman AV, Sharma R, Afzal NM, et al. Stricturing and Fistulizing Crohn's Disease Is Associated with Anti-tumor Necrosis Factor-Induced Psoriasis in Patients with Inflammatory Bowel Disease. Dig Dis Sci. 2018;63(9):2430-2438. doi:10.1007\/s10620-018-5096-2","DOI":"10.1007\/s10620-018-5096-2"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Laranjeira N, Fonseca J, Meira T, Freitas J, Valido S, Leit\u00e3o J. Oral mucosa lesions and oral symptoms in inflammatory bowel disease patients. Arq Gastroenterol. 2015;52(2):105-110. doi:10.1590\/S0004-28032015000200006","DOI":"10.1590\/S0004-28032015000200006"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Ampuero J, Rojas-Feria M, Castro-Fern\u00e1ndez M, Cano C, Romero-G\u00f3mez M. Predictive factors for erythema nodosum and pyoderma gangrenosum in inflammatory bowel disease. J Gastroenterol Hepatol. 2014;29(2):291-295. doi:10.1111\/jgh.12352","DOI":"10.1111\/jgh.12352"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Alinaghi F, Tekin HG, Burisch J, Wu JJ, Thyssen JP, Egeberg A. Global Prevalence and Bidirectional Association Between Psoriasis and Inflammatory Bowel Disease-A Systematic Review and Meta-analysis. J Crohns Colitis. 2020;14(3):351-360. doi:10.1093\/ecco-jcc\/jjz152","DOI":"10.1093\/ecco-jcc\/jjz152"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Denadai R, Teixeira FV, Steinwurz F, Romiti R, Saad-Hossne R. Induction or exacerbation of psoriatic lesions during anti-TNF-\u03b1 therapy for inflammatory bowel disease: a systematic literature review based on 222 cases. J Crohns Colitis. 2013;7(7):517-524. doi:10.1016\/j.crohns.2012.08.007","DOI":"10.1016\/j.crohns.2012.08.007"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Cleynen I, Van Moerkercke W, Billiet T, et al. Characteristics of Skin Lesions Associated With Anti-Tumor Necrosis Factor Therapy in Patients With Inflammatory Bowel Disease: A Cohort Study. Ann Intern Med. 2016;164(1):10-22. doi:10.7326\/M15-0729","DOI":"10.7326\/M15-0729"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Au M, Heddle G, Young E, et al. Anti-tumour necrosis factor-induced skin rashes in inflammatory bowel disease: a systematic review and evidence-based management algorithm. Intern Med J. 2023;53(10):1854-1865. doi:10.1111\/imj.15859","DOI":"10.1111\/imj.15859"}],"container-title":["Acta medica Lituanica"],"original-title":[],"link":[{"URL":"https:\/\/www.zurnalai.vu.lt\/AML\/article\/download\/35011\/34771","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/zurnalai.vu.lt\/\/AML\/article\/download\/35011\/33765","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.zurnalai.vu.lt\/AML\/article\/download\/35011\/34772","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.zurnalai.vu.lt\/AML\/article\/download\/35011\/34771","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T00:00:34Z","timestamp":1753920034000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.zurnalai.vu.lt\/AML\/article\/view\/35011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,17]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,2,27]]}},"URL":"https:\/\/doi.org\/10.15388\/amed.2024.31.1.23","relation":{},"ISSN":["2029-4174","1392-0138"],"issn-type":[{"type":"electronic","value":"2029-4174"},{"type":"print","value":"1392-0138"}],"subject":[],"published":{"date-parts":[[2024,9,17]]}}}